Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Latigo Biotherapeutics, Inc.: 5AM Ventures VI, L.P. discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

5AM Ventures VI, L.P. disclosed a stake exceeding 5% in Latigo Biotherapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001753037-26-000010). The filing signals the venture firm's passive position in the clinical-stage biotech, though exact share counts and percentages were not specified in the disclosure. The move matters because 13G filings often precede broader institutional interest in small-cap biotech names. Investors will watch for further 13G/13D filings and any updates on Latigo's pipeline progress.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

5AM Ventures VI, L.P., Latigo Biotherapeutics, Inc.